FindTrial
Sign In

BIOEMBRACE-1

A pilot evaluation of prognostic molecular and serum biomarkers of disease recurrence after chemoradiation in patients with locally advanced cervical cancer from EMBRACE study group (BIOEMBRACE-1) - BIO-EMBRACE-1

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/03/018331
Enrollment
300
Registered
2019-03-29
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Tata memorial Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) The study population will include patients recruited in the EMBRACE and EMBRACE-II studies that have completed treatment and have baseline and follow up information available. 2) Tumour sample inclusion for the molecular study necessitates that at least >40% of the sample is composed of viable tumour cells.

Exclusion criteria

Exclusion criteria: Tumour samples with less than < 40% viable tumour cells will be excluded

Design outcomes

Primary

MeasureTime frame
Results from these multi-centric study will inform us about the prognostic role of new markers so that new drugs can be evaluated in future.Timepoint: 3 Years—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

Austria, Denmark, France, India, Netherlands, United Kingdom

Contacts

Public ContactDr Supriya Chopra

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)

supriyasastri@gmail.com9930958309

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026